Payment overview · 2025
General Payments
$619.88
13 reported records · 4 companies
Healthcare provider profile · identity verified
Igor Zhuravenko, MD
Allopathic & Osteopathic Physicians|Internal Medicine · BROOKLYN, NY · NPI 1962438598
Verified facts
What the public records show
CMS Open Payments records show Igor Zhuravenko, MD received $619.88 in general payments during 2025 across 13 reported records.
Aimmune Therapeutics, Inc. accounted for 63.2% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 5 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Creon, Farxiga, Linzess, Zenpep.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ARMOUR THYROID as an associated drug or biological on 50 records involving 11 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Armour Thyroid by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported CREON as an associated drug or biological on 91561 records involving 20616 distinct recipient NPIs. Public Medicare Part D data also shows 139 claims for Creon by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 196 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 343 claims for Synthroid by this doctor in 2024.
Aimmune Therapeutics, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ZENPEP as an associated drug or biological on 32144 records involving 12432 distinct recipient NPIs. Public Medicare Part D data also shows 157 claims for Zenpep by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 70 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Symbicort by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Aimmune Therapeutics, Inc. | Unresolved — no canonical attribution shown | $391.78 | 63.2% | 4 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $106.58 | 17.2% | 4 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $66.05 | 10.7% | 3 | 2025 |
| Medtronic, Inc. |
Medtronic, Inc. exact · evidence 2025-07-22 |
$55.47 | 8.9% | 2 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $619.88 | 13 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| ZENPEP Normalized: zenpep |
Drug | Aimmune Therapeutics, Inc. | $391.78 | 4 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $106.58 | 4 | 2025 |
Source payment records
|
|||||
| MINIMED 780G Normalized: minimed 780g |
Device | Medtronic, Inc. | $55.47 | 2 | 2025 |
Source payment records
|
|||||
| CREON Normalized: creon |
Drug | ABBVIE INC. | $41.41 | 2 | 2025 |
Source payment records
|
|||||
| LINZESS Normalized: linzess |
Drug | ABBVIE INC. | $20.57 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| CREON creon |
2025 | Creon | 2024 | 139 | exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 70 | exact normalized | Medicare Part D |
| LINZESS linzess |
2025 | Linzess | 2024 | 196 | exact normalized | Medicare Part D |
| ZENPEP zenpep |
2025 | Zenpep | 2024 | 157 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | ARMOUR THYROID open payments reported associated product |
CMS Open Payments — General Payments 50 supporting records · 11 recipient NPIs · example record 1201517088 |
Armour Thyroid · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | CREON open payments reported associated product |
CMS Open Payments — General Payments 91561 supporting records · 20616 recipient NPIs · example record 1201352608 |
Creon · 2024 Exact normalized brand match · 1 Part D row |
139 | 25 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
196 | 27 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
343 | 38 |
| Aimmune Therapeutics, Inc. Exact reporting entity; no affiliate inference |
2025 | ZENPEP open payments reported associated product |
CMS Open Payments — General Payments 32144 supporting records · 12432 recipient NPIs · example record 1249641927 |
Zenpep · 2024 Exact normalized brand match · 1 Part D row |
157 | 22 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
70 | 14 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Rosuvastatin Calcium | Rosuvastatin Calcium | 470 | 61 |
| Vascepa | Icosapent Ethyl | 461 | 57 |
| Metoprolol Succinate | Metoprolol Succinate | 429 | 50 |
| Atorvastatin Calcium | Atorvastatin Calcium | 419 | 60 |
| Synthroid | Levothyroxine Sodium | 343 | 38 |
| Amlodipine Besylate | Amlodipine Besylate | 319 | 49 |
| Gabapentin | Gabapentin | 295 | 50 |
| Acarbose | Acarbose | 289 | 34 |
| Allopurinol | Allopurinol | 287 | 34 |
| Dexlansoprazole Dr | Dexlansoprazole | 274 | 33 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 251 | 24 |
| Pantoprazole Sodium | Pantoprazole Sodium | 221 | 28 |
| Omeprazole | Omeprazole | 216 | 34 |
| Furosemide | Furosemide | 213 | 39 |
| Tamsulosin Hcl | Tamsulosin Hcl | 207 | 28 |
| Linzess | Linaclotide | 196 | 27 |
| Montelukast Sodium | Montelukast Sodium | 186 | 44 |
| Clopidogrel | Clopidogrel Bisulfate | 174 | 24 |
| Eliquis | Apixaban | 173 | 18 |
| Clonidine | Clonidine | 163 | 19 |
| Diclofenac Sodium | Diclofenac Sodium | 157 | 20 |
| Zenpep | Lipase/Protease/Amylase | 157 | 22 |
| Trulicity | Dulaglutide | 156 | 15 |
| Ranolazine Er | Ranolazine | 149 | 16 |
| Trazodone Hcl | Trazodone Hcl | 149 | 21 |
| Creon | Lipase/Protease/Amylase | 139 | 25 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 139 | 18 |
| Pentoxifylline | Pentoxifylline | 127 | 14 |
| Tradjenta | Linagliptin | 121 | 15 |
| Metformin Hcl | Metformin Hcl | 118 | 18 |
| Hydralazine Hcl | Hydralazine Hcl | 110 | 17 |
| Losartan Potassium | Losartan Potassium | 110 | 18 |
| Glimepiride | Glimepiride | 106 | 21 |
| Lisinopril | Lisinopril | 106 | 13 |
| Alcohol Prep Pads | Alcohol Antiseptic Pads | 104 | 22 |
| Icosapent Ethyl | Icosapent Ethyl | 104 | 21 |
| Janumet | Sitagliptin Phos/Metformin Hcl | 104 | 15 |
| Famotidine | Famotidine | 103 | 11 |
| Raloxifene Hcl | Raloxifene Hcl | 99 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 98 | 15 |
| Atenolol | Atenolol | 97 | 12 |
| Clonidine Hcl | Clonidine Hcl | 89 | 21 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 89 | 12 |
| Fluticasone Propionate | Fluticasone Propionate | 88 | 33 |
| Glipizide-Metformin | Glipizide/Metformin Hcl | 87 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 85 | 19 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 84 | 36 |
| Meclizine Hcl | Meclizine Hcl | 83 | 20 |
| Carvedilol | Carvedilol | 80 | 13 |
| Finasteride | Finasteride | 77 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 77 | 14 |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 75 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 74 | 15 |
| Farxiga | Dapagliflozin Propanediol | 70 | 14 |
| Glipizide Er | Glipizide | 70 | suppressed |
| Namzaric | Memantine Hcl/Donepezil Hcl | 63 | suppressed |
| Chlorhexidine Gluconate | Chlorhexidine Gluconate | 62 | 17 |
| Januvia | Sitagliptin Phosphate | 62 | suppressed |
| Torsemide | Torsemide | 62 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 61 | 16 |
| Methimazole | Methimazole | 59 | suppressed |
| Hydrochlorothiazide | Hydrochlorothiazide | 58 | suppressed |
| Single Use Swab | Alcohol Antiseptic Pads | 57 | 13 |
| Pravastatin Sodium | Pravastatin Sodium | 55 | suppressed |
| Levothyroxine Sodium | Levothyroxine Sodium | 54 | 11 |
| Meloxicam | Meloxicam | 53 | 12 |
| Betamethasone Dipropionate | Betamethasone Dipropionate | 51 | 12 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 51 | suppressed |
| Aspirin-Dipyridamole Er | Aspirin/Dipyridamole | 49 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 49 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 49 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 48 | suppressed |
| Valsartan | Valsartan | 48 | suppressed |
| Prednisone | Prednisone | 47 | 33 |
| Easy Touch Alcohol Prep Pads | Alcohol Antiseptic Pads | 46 | suppressed |
| Lidocaine | Lidocaine | 46 | 13 |
| Edarbyclor | Azilsartan Med/Chlorthalidone | 43 | suppressed |
| Sucralfate | Sucralfate | 41 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 40 | suppressed |
| Azithromycin | Azithromycin | 39 | 34 |
| Propranolol Hcl | Propranolol Hcl | 39 | suppressed |
| Ozempic | Semaglutide | 38 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 38 | suppressed |
| Cilostazol | Cilostazol | 37 | suppressed |
| Cefuroxime | Cefuroxime Axetil | 35 | 32 |
| Nifedipine Er | Nifedipine | 35 | suppressed |
| Potassium Citrate Er | Potassium Citrate | 33 | suppressed |
| Alcohol Pads | Alcohol Antiseptic Pads | 32 | suppressed |
| Potassium Chloride | Potassium Chloride | 32 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 31 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 31 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 29 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 28 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 28 | suppressed |
| Amlodipine-Valsartan | Amlodipine Besylate/Valsartan | 27 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 27 | suppressed |
| Procto-Med Hc | Hydrocortisone | 26 | suppressed |
| Prolia | Denosumab | 26 | 16 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 26 | suppressed |
| Febuxostat | Febuxostat | 25 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 25 | suppressed |
| Exelon | Rivastigmine | 23 | suppressed |
| Cinacalcet Hcl | Cinacalcet Hcl | 22 | suppressed |
| Multaq | Dronedarone Hcl | 22 | suppressed |
| Ezetimibe | Ezetimibe | 21 | suppressed |
| Simvastatin | Simvastatin | 21 | suppressed |
| Telmisartan | Telmisartan | 20 | suppressed |
| Ultra-Fine Micro Pen Needle | Pen Needle, Diabetic | 20 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 20 | suppressed |
| Advair Hfa | Fluticasone Propion/Salmeterol | 19 | suppressed |
| Clotrimazole | Clotrimazole | 19 | suppressed |
| Dutasteride | Dutasteride | 19 | suppressed |
| Fluocinonide | Fluocinonide | 19 | suppressed |
| Glipizide | Glipizide | 19 | suppressed |
| Ammonium Lactate | Ammonium Lactate | 18 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 18 | suppressed |
| Metoprolol Tartrate | Metoprolol Tartrate | 18 | suppressed |
| Mupirocin | Mupirocin | 18 | suppressed |
| Novolog Flexpen | Insulin Aspart | 18 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 17 | suppressed |
| Repaglinide | Repaglinide | 17 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 16 | suppressed |
| Dapagliflozin | Dapagliflozin Propanediol | 16 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 16 | suppressed |
| Ketoconazole | Ketoconazole | 16 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 16 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 16 | suppressed |
| Fludrocortisone Acetate | Fludrocortisone Acetate | 15 | suppressed |
| Mounjaro | Tirzepatide | 15 | suppressed |
| Silver Sulfadiazine | Silver Sulfadiazine | 15 | suppressed |
| Digoxin | Digoxin | 14 | suppressed |
| Nitroglycerin | Nitroglycerin | 14 | suppressed |
| Norvasc | Amlodipine Besylate | 14 | suppressed |
| Novofine 32 | Pen Needle, Diabetic | 14 | suppressed |
| Spironolactone | Spironolactone | 14 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 14 | suppressed |
| Armour Thyroid | Thyroid,pork | 13 | suppressed |
| Benicar Hct | Olmesartan/Hydrochlorothiazide | 13 | suppressed |
| Folic Acid | Folic Acid | 13 | suppressed |
| Mirtazapine | Mirtazapine | 13 | suppressed |
| Saxagliptin-Metformin Er | Saxagliptin Hcl/Metformin Hcl | 13 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 13 | suppressed |
| Uloric | Febuxostat | 13 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 12 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 12 | suppressed |
| Colchicine | Colchicine | 12 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 12 | suppressed |
| Janumet Xr | Sitagliptin Phos/Metformin Hcl | 12 | suppressed |
| Jardiance | Empagliflozin | 12 | suppressed |
| Modafinil | Modafinil | 12 | suppressed |
| Mupirocin | Mupirocin Calcium | 12 | suppressed |
| Nitroglycerin Patch | Nitroglycerin | 12 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 12 | suppressed |
| Pro Comfort Alcohol Pads | Alcohol Antiseptic Pads | 12 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 12 | suppressed |
| Zypitamag | Pitavastatin Magnesium | 12 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 11 | suppressed |
| Fluticasone-Salmeterol Hfa | Fluticasone Propion/Salmeterol | 11 | suppressed |
| Livalo | Pitavastatin Calcium | 11 | suppressed |
| Lorazepam | Lorazepam | 11 | suppressed |
| Memantine Hcl | Memantine Hcl | 11 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 11 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 11 | suppressed |
| Trulance | Plecanatide | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $619.88 · 13 records | Aimmune Therapeutics, Inc. | CREON, FARXIGA, LINZESS, MINIMED 780G, ZENPEP | 7 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Creon play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error